Dunad Therapeutics
Tunable covalent chemistry with a deep understanding of disease biology to develop transformational medicines.
Tunable covalent chemistry with a deep understanding of disease biology to develop transformational medicines.
Dunad Therapeutics, founded in 2020 and headquartered in the United Kingdom, is a biotechnology and pharmaceutical company with the slogan "Tunable covalent chemistry with a deep understanding of disease biology to develop transformational medicines." The company's last investment of $24.00M came from prominent investors including BioGeneration Ventures, Novartis, and Epidarex Capital on 02 November 2021. leveraging proprietary, tunable covalent chemistry and a profound knowledge of disease biology, Dunad Therapeutics aims to discover and develop groundbreaking medications that selectively and durably target disease drivers within the Biotechnology and Pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $24.00M | 3 |
|
02 Nov 2021 |
| Seed Round | Unknown | 1 |
|
23 Mar 2021 |
No recent news or press coverage available for Dunad Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
